Lista de obras -

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

artículo científico publicado en 2019

Avoiding Overtreatment of Ductal Carcinoma in situ

artículo científico publicado en 2019

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency

artículo científico publicado en 2016

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer

artículo científico publicado en 2020

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

artículo científico publicado en 2021

Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes

artículo científico publicado en 2014

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study

artículo científico publicado en 2018

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy

artículo científico publicado en 2014

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance

artículo científico publicado en 2022

Correction: Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

scientific article published on 01 May 2019

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS

artículo científico publicado en 2019

Ductal carcinoma in situ: to treat or not to treat, that is the question

scientific article published on 09 July 2019

EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy

artículo científico publicado en 2019

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients

artículo científico publicado en 2017

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

artículo científico publicado en 2016

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer

artículo científico publicado en 2015

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

artículo científico publicado en 2022

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

artículo científico publicado en 2014

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study

artículo científico publicado en 2016

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

artículo científico publicado en 2012

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

artículo científico publicado en 2017

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

artículo científico publicado en 2016

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

artículo científico publicado en 2015

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile

artículo científico publicado en 2013

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses

scientific article published on 25 April 2019

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

scientific article published on 10 May 2019

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

artículo científico publicado en 2020

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness ⬇️

artículo científico publicado el 27 de octubre de 2011

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression

artículo científico publicado en 2020

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study

artículo científico publicado en 2019

Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients

artículo científico publicado en 2019

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms

artículo científico publicado en 2015

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.

artículo científico publicado en 2012

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification

scientific article published on 14 February 2020

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review

artículo científico publicado en 2020

Lista de obras de

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

Avoiding Overtreatment of Ductal Carcinoma in situ

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance

Correction: Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS

Ductal carcinoma in situ: to treat or not to treat, that is the question

EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness ⬇️

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study

Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review

[Ductal carcinoma in situ: the balance between over- and undertreatment]